We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-11.08%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$392M
AUM Growth
+$83.3M
Cap. Flow
+$144M
Cap. Flow %
36.67%
Top 10 Hldgs %
78.59%
Holding
39
New
6
Increased
17
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$25.2M
2
VERA icon
Vera Therapeutics
VERA
+$17.8M
3
BNR
Burning Rock Biotech
BNR
+$15.7M
4
CLDX icon
Celldex Therapeutics
CLDX
+$11M
5
NTRA icon
Natera
NTRA
+$10.1M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$9.32M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.2M
3
RDUS
Radius Health, Inc.
RDUS
+$1.64M
4
KRYS icon
Krystal Biotech
KRYS
+$1.22M
5
WVE icon
Wave Life Sciences
WVE
+$414K

Sector Composition

Rank Sector Weight
1 Healthcare 97.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
$70.3M 17.95%
2,200,000
+860,678
+64% +$25.2M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$48.3M 12.34%
2,512,240
+579,440
+30% +$9.65M
NTRA icon
3
Natera
NTRA
$37.5B
$43.9M 11.21%
1,239,047
+272,647
+28% +$10.1M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.77B
$30.5M 7.8%
1,132,259
+379,225
+50% +$11M
TVTX icon
5
Travere Therapeutics
TVTX
$5.33B
$29.9M 7.64%
1,235,151
+364,233
+42% +$9.16M
VERA icon
6
Vera Therapeutics
VERA
$2.54B
$20.7M 5.29%
1,522,712
+1,020,384
+203% +$17.8M
GOSS icon
7
Gossamer Bio
GOSS
$66.5M
$19.7M 5.02%
2,350,448
+517,744
+28% +$4.01M
BIIB icon
8
Biogen
BIIB
$29.9B
$16.1M 4.11%
78,951
+40,715
+106% +$8.32M
PCVX icon
9
Vaxcyte
PCVX
$7.89B
$15.7M 4.02%
723,781
+144,141
+25% +$3.34M
BNR
10
Burning Rock Biotech
BNR
$94.4M
$12.5M 3.2%
430,000
+352,689
+456% +$15.7M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.37B
$9.91M 2.53%
+936,563
New +$9.66M
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$9.67M 2.47%
900,000
+326,484
+57% +$2.69M
COGT icon
13
Cogent Biosciences
COGT
$6.79B
$9.02M 2.3%
+1,000,000
New +$6.83M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$6.83M 1.74%
590,143
+317
+0.1% +$4.26K
LQDA icon
15
Liquidia Corp
LQDA
$7.67B
$6.54M 1.67%
1,500,718
+341,044
+29% +$1.76M
AMRN
16
Amarin Corp
AMRN
$284M
$5.97M 1.53%
200,495
+85,791
+75% +$3.7M
WVE icon
17
Wave Life Sciences
WVE
$1.12B
$5.51M 1.41%
1,696,735
-214,993
-11% -$414K
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.32B
$5.32M 1.36%
175,000
-308,270
-64% -$9.32M
CNCE
19
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$4.21M 1.08%
+1,000,000
New +$3.96M
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$3.69M 0.94%
757,848
+88,748
+13% +$568K
CLDX icon
21
CALL
Celldex Therapeutics
CLDX
$2.77B
$2.48M 0.63%
+246,400
New +$7.16M
MRUS
22
DELISTED
Merus
MRUS
$2.35M 0.6%
103,627
-13,137
-11% -$274K
FATE icon
23
Fate Therapeutics
FATE
$281M
$2.01M 0.51%
81,064
-10,273
-11% -$283K
AFMD
24
DELISTED
Affimed
AFMD
$1.94M 0.5%
70,103
+35,306
+101% +$1.21M
AKUS
25
DELISTED
Akouos Inc
AKUS
$1.8M 0.46%
383,784
-4,108
-1% -$14.5K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Kynam Capital Management held 39 positions worth $392M, up 27% from $308M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Kynam Capital Management deployed $144M of net new capital in Q2 2022, opening 6 new positions and adding to 17 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 936,563 shares worth $9.91M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $9.32M trimmed.

  • Kynam Capital Management's largest Q2 2022 buy was BioCryst Pharmaceuticals: 936,563 shares worth $9.91M.
  • Kynam Capital Management added most to Global Blood Therapeutics, Inc. in Q2 2022, an estimated $25.2M increase.
  • Kynam Capital Management's biggest Q2 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $9.32M.
  • Kynam Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q2 2022, selling an estimated $6.2M.
  • Kynam Capital Management's ten largest holdings make up 79% of its $392M portfolio in Q2 2022.
  • Kynam Capital Management opened 6 new positions and closed 5 in Q2 2022.
  • Kynam Capital Management's portfolio value rose 27% quarter-over-quarter to $392M.

Based on Kynam Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.